Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report
The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...
top of page
NEWS
- Dec 22, 2023
Biden’s New Medicine Rules Have Pharmaceutical Companies Slow-Walking New Therapies
Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...
- Nov 21, 2023
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
Employers and unions are getting fed up with the firms they have used for years to help control their spending on prescription...
- Oct 24, 2023
Pharma Industry Readies for Drug Pricing Lawsuit Second Wave
Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug...
- Sep 19, 2023
Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve...
- Sep 6, 2023
AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the...
- Aug 29, 2023
HHS Drops First 10 Drugs for Medicare Drug Price Negotiation
The U.S. Department of Health and Human Services (HHS) on Tuesday announced the first 10 drugs covered under Medicare Part D to be...
- Aug 29, 2023
Biden administration chooses first 10 drugs for Medicare price negotiations
WASHINGTON — Medicare can now negotiate lower prices for 10 common high-price drugs, cutting out-of-pocket costs for an estimated 9...
- Aug 28, 2023
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world...
- Jul 27, 2023
Roche: Have Abandoned Some Trials Due to U.S. Drug Pricing Plans
By Reuters FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration...
- Jul 6, 2023
Genentech CEO Alexander Hardy warns of 'unintended consequences' from the Inflation Reduction Act
It’s been almost one year since Congress and the Biden administration passed the Inflation Reduction Act (IRA), and so far leaders in the...
- Jun 28, 2023
On conference circuit, biotechs lobby for their identity as new IRA drug pricing reforms take hold
The biotech industry split off into two conference camps in early June: Oncology researchers headed to Chicago for the American Society...
- Jun 21, 2023
Biopharma Execs Weigh Controversial Move: Opting Out of Medicare to Escape Drug Price Negotiations
A panel hosted last week by JP Morgan and the industry group PhRMA further hinted at possible sweeping changes to the U.S. drug...
- Jun 16, 2023
Inflation Reduction Act is destabilizing investment in drug innovation, execs say
The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says. The Inflation...
- Jun 14, 2023
IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says
As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you...
- Jun 5, 2023
Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster...
- Jun 2, 2023
IRA forcing pharmas to leave cancer patients in the lurch, CEOs say
The IRA is leading pharmas to forego fast-to-patient development strategies in favor of getting onto the market first with the largest...
- May 19, 2023
Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will...
- Mar 17, 2023
Amgen cites inflation, pressure on drug prices in 450-person layoff
Amgen is laying off about 450 workers, the company told Endpoints News, just two months after letting go 300 staffers...
- Jan 5, 2023
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones
FOSTER CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a ...
- 4 days ago
Fact Checking the Inflation Reduction Act’s Real-World Impact and Consequences
As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...
- Sep 9
Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem
In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act – established a...
- Sep 5
Watch: California leaders highlight biopharma innovation, collaboration and policy progress
During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...
- Aug 29
Don’t Throw Out 40 Years of Innovation by Dismantling IP Protections
While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...
- Aug 28
Policymakers: Protect & Maximize U.S. Intellectual Property for Biopharma Innovation that Helps Patients
American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....
- Aug 27
State-By-State Data Showcases Biopharma’s Impact on Local Economics and Innovation
We Work For Health recently unveiled a new set of one-page resources designed to highlight the significant impact of the...
- Aug 22
Protecting the Drug Discovery Pipeline
A version of this blog originally published as an op-ed in The Center Square in Arizona. We're sharing it here with additional updates...
- Aug 15
We Work For Health Statement on IRA Medicare Price Setting Announcement
Aug. 15, 2024 FOR IMMEDIATE RELEASE WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...
- Aug 14
A Guide to Understanding the Administration’s Announcement on Medicare Drug Pricing
The Biden administration this week is expected to claim victory on its stated goal of lowering drug prices for seniors. While the...
- Aug 6
10 Reasons Biopharma Innovation Needs Strong IP Protections
By Dan Leonard, WWFH Executive Director Intellectual property (IP) plays a crucial role in the success of the pharmaceutical and biotech...
- Jul 30
Inflation Reduction Act Causes Medicare Part D Premiums To Increase Again
On Monday, the Centers for Medicare and Medicaid Services (CMS) announced 2025 premiums for Medicare Part D plans will increase again....
- Jul 2
We Work For Health's Comments on IPAY 2027 draft guidance
Meena Seshamani, M.D., Ph.D. CMS Deputy Administrator and Director of the Center for Medicare Centers for Medicare & Medicaid Services...
- Jun 28
New Research Shows Alarming Drop in Neurology Innovation Due To IRA’s Small Molecule ‘Pill Penalty’
During an event on Capitol Hill this week, California Rep. Scott Peters highlighted a graphic that clearly illustrates the distorted...
- Jun 25
New Report Demonstrates How the IRA’s “Pill Penalty” is Setting Back the Development of Non-Opioid Pain Medicine
Despite the significant demand for effective non-opioid medications for the treatment of pain, a recent report from the Pioneer Institute...
- Jun 24
We Work For Health Honors Rep. Scott Peters with Healthcare Leadership Innovation Award
SAN DIEGO – At a We Work For Health roundtable on June 20, the organization and its partners honored Rep. Scott Peters (CA-50) with the...
- Jun 21
As NIST Finalizes March-in Guidance, Innovation Community Continues to Convey Opposition
The National Institute of Standards and Technology (NIST) may soon finalize its controversial proposal to expand the scope of the...
- Jun 10
New Data Reveals Strong Economic Impact of Texas Biopharmaceutical Industry
For Immediate Release June 5, 2024 Contact: Lisa Glass 512-695-3569 / lglass@rosscomm.com New Data Reveals Strong Economic Impact of...
- Jun 5
The Inflation Reduction Act is Hurting Medicare Access and Increasing Patients’ Costs
This week, the largest not-for-profit health insurance provider in Missouri, Blue KC, announced it will leave the Medicare Advantage...
- May 1
CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule allowing Medicare Advantage and Part D health plans to...
- Apr 26
Statement by We Work For Health Executive Director Dan Leonard on World IP Day
FOR IMMEDIATE RELEASE April 26, 2024 WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...
- Apr 3
Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline
Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...
- Mar 28
Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma
We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and...
- Mar 12
Vendors Power America's Biopharmaceutical Industry
We Work For Health recently released new employment, vendor and supplier expenditure data that showcases the vital contributions of these...
- Mar 7
President Biden’s State of the Union Call for IRA Expansion Hurts Patients, Workers, and U.S. Leadership
During his State of the Union address Thursday night, President Biden called for Congress to expand the Inflation Reduction Act to...
- Feb 29
House Reviews the ORPHAN Cures Act
On Feb. 29, the House Energy and Commerce Subcommittee on Health held a hearing to review a number of bills that impact those living with...
- Feb 13
Biden's Attempts to Lower Drug Costs Are Sabotaging Biosimilar Competition and Are Destined For Failure
The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...
- Feb 1
Statement By We Work For Health on the Ensuring Pathways to Innovative Cures (EPIC) Act
Feb. 01, 2024 FOR IMMEDIATE RELEASE Washington, DC (Feb. 01, 2024) – We Work For Health has issued the following statement from Executive...
- Jan 31
The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments
The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...
- Jan 31
How American Patients Will Bear the Cost of Government Price Controls
Today, patients in the United States have greater access to the latest lifesaving and life-altering medical treatments than anywhere...
- Jan 28
The Bayh-Dole Act works. It’s not time to change it.
Forty-three years ago, a young U.S. Sen. Joe Biden voted for a transformative policy reform that subsequently catalyzed upwards of $2...
- Jan 26
Biden Administration’s Threat to Pharmaceutical Innovation Endangers Lives
The idea that the government could forcibly seize ownership of a groundbreaking invention you created is chilling. But that is the...
- Jan 25
Biden's Bayh-Dole Act proposal misuses 'march-in rights'
The Biden administration may soon gut the Bayh-Dole Act, one of our nation's most important and impactful laws that also supports nearly...
- Jan 25
Medicare prescription price controls will hurt seniors
The inflationary spiral that drove prices up during the first years of the Biden administration has ended. That’s the good news. The bad...
- Jan 23
Protect Future Discoveries By Rejecting The TRIPS Patent Waiver
Investment in U.S. biotechnology could be about to plummet, with major implications for future innovation. It all depends on the outcome...
- Jan 22
International Association of Fire Fighters' General President Sends Letter to U.S. Secretary of Commerce Opposing World Trade Organization TRIPS Waiver
The International Association of Fire Fighters' General President, Edward Kelly, sent the following letter to U.S. Secretary of Commerce...
- Jan 22
Breaking the Law That Led to 7,739 Patents and 1,000 Startups in 2022 Alone
The Biden administration is out to break the law. It’s proposed a framework for federal agencies to impose “march-in” rights on patented...
- Jan 21
A patent waiver is a bad deal for WA
If Washington state were a country, it would be the 26th-largest economy in the world. Last year, our economic output reached more than...
- Jan 19
Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report
The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...
- Jan 19
Biden Administration Policy Jeopardizes The System That Gave Us Gene Editing
The FDA just approved the first drug based on CRISPR, the revolutionary gene-editing technology. The medication treats sickle cell...
- Jan 18
Price Fixing Never Works
Government is a terrible allocator of resources and equally bad at interfering with free markets. A great example is the ham-handed way...
- Jan 18
Don't let geopolitics erode America's research engine
Patents and other intellectual property rights are at the heart of American innovation, and enshrined in the U.S. Constitution. Right now...
- Jan 18
New Study Reinforces That Expansion of IRA Price Setting Would Further Crush Patient Health, Innovative Treatments and U.S. Biopharma Jobs
The Latest Plan from Some House Democrats to Expand Government Drug Price Controls Will Lead to Further Declines in New Treatments for...
- Jan 14
President Biden’s domestic technology seizure plan
Last month, the Biden administration released a radical proposal that — if finalized — would decimate American innovation across the most...
- Jan 11
New patent proposal would kill innovation across industries
As the 2024 general election nears, President Joe Biden is making dramatic policy announcements in an effort to energize the voter base....
- Jan 9
White House’s Drug Patent Plan Undercuts Research and Innovation
On Dec. 7, the White House announced a plan it claims will lower prescription drug costs. It centers on using a 43-year-old law—the...
- Jan 8
Biden’s plan to reduce drug prices will damage innovation
Last month, the Biden administration issued a proposal that could be very damaging to American innovation. The plan would empower the...
- Jan 8
IRA's impact on medical innovation
The debate over drug price negotiation policies, particularly those in the Inflation Reduction Act, has become the centerpiece of...
- Jan 7
‘March-in rights’ are part of Biden’s march toward socialized medicine
President Joe Biden has crossed the line from ill-advised policy to government theft of intellectual property in the White House’s latest...
- Jan 5
Biden voted for the Bayh-Dole Act 44 years ago – but the administration’s plans to reinterpret it could undermine decades of world-leading U.S. innovation
Historically Black Colleges and Universities (HBCUs) could soon become even bigger innovation hubs, thanks to measures advanced by...
bottom of page